touchIN CONVERSATION

Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice

Access to this content is not permitted for healthcare professionals based in the US.

Back to Home
Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues

    Downloads
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Kausik Ray

    Department of Public Health and Primary Care, Imperial Clinical Trials Unit, Imperial College London, UK

    Prof. Ray is currently president of the European Atherosclerosis Society, chair of the World Heart Federation Roadmap on Cholesterol 2021–2022, chair of the Global Council for Heart Health, national lead for the CVD NIHR Academic Research Collaboration, and clinical director for Health Data Research UK and Discover-NOW Digital Innovation Hub. read more

    He received his medical education (MB ChB) at the University of Birmingham Medical School, his MD at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School, and an MPhil in epidemiology from the University of Cambridge.

    Prof. Ray’s research involves lipids, diabetes and population health, and he serves as global lead for several trials and registries. He leads the international development programme for inclisiran, and is playing a key role in the development programme of bempedoic acid and PCSK9 monoclonal antibodies. He initiated the Familial Hypercholesterolaemia (FH) Studies Collaboration, the only global registry of FH, as well as multinational European registries, such as DA VINCI, HEYMANS and SANTORINI, all of which are helping to shape global health policy.

    Prof. Ray has had >100,000 citations, and since 2018, has been recognized annually by Clarivate Analytics as among the top 0.1% of authors in global medicine.

    Disclosures

    Prof. Kausik Ray discloses: Advisory board or panel fees from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Esperion, Kowa, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Resverlogix and Silence Therapeutics. Grants/research support from Amgen, Daiichi Sankyo and Regeneron. Speaker’s bureau fees from Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Lupin, Novartis, Novo Nordisk, Pfizer and Sanofi. Stocks/shareholder (self-managed) in Cargene Therapeutics and Pemi31 Therapeutics.
    Dr. med. Mahir Karakas

    University Medical Center, Hamburg, Germany

    Dr. med. Mahir Karakas is a specialist in cardiology, intensive care medicine, emergency medicine and genetic counselling at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany. In addition, he is the designated W3-Professor for Translational Research and Innovative Clinical Trials at Hamburg University (Else Kröner-Fresenius-Foundation). read more

    After a residency position at the University of Frankfurt, and a research fellowship at Ludwig-Maximilians-University (LMU), Munich, Dr. med. Karakas continued his residency at the University of Ulm from 2009 to 2013. He has been a senior physician/consultant at the University Medical Center Hamburg-Eppendorf since 2014.

    His research interests include the prevention of cardiovascular disease, biomarkers of cardiometabolic diseases, clinical pharmacology of cardiovascular compounds and animal models of myocardial infarction. He is involved in multiple multicentre clinical trials evaluating the effects of new pharmacologic compounds on cardiometabolic diseases, infectious diseases and sepsis, and heads the steering committee of various investigator-initiated clinical trials in acute coronary syndrome, atrial fibrillation, heart failure, cardiogenic shock, COVID-19, acute respiratory distress syndrome and sepsis.

    Disclosures

    Dr. med. Karakas discloses: Advisory board or panel, consultancy and speaker’s bureau fees from 4TEEN4 Pharmaceuticals, Adrenomed AG, Sphingotec and Vifor Pharma. Grants/research support from Adrenomed AG and Vifor Pharma.
    Back to Faculty
    touchCARDIO touchCARDIO
    Now Playing:
    Up Next:
    Take CE/CME Test
    Start activity
     
    Lipid-lowering goals in patients with dyslipidemias: What do the guidelines say?
    Strategies to reduce ASCVD risk: The latest guidelines and clinical data on lipid-lowering therapies
    Managing dyslipidemias in special patient populations: What are the important considerations?
    Take CE/CME Test

    touchIN CONVERSATION
    A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation. Close

    Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice

    Faculty Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in French, German, Spanish.
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Choose appropriate lipid goals for patients with dyslipidemias and at risk of ASCVD, considering the latest guidelines
    • Formulate guideline-based and forward-thinking strategies to reduce ASCVD risk in patients with dyslipidemias using appropriate lipid- and lipoprotein-lowering therapies
    • Recognize special populations of patients with dyslipidemias and apply important considerations when treating them with lipid- and lipoprotein-lowering therapies
    Overview

    In this activity, experts in the management of dyslipidemias and ASCVD respond to questions from the cardiology community on lipid goals for patients with dyslipidemias and at risk of ASCVD. They discuss strategies to reduce ASCVD risk in such patients using appropriate lipid- and lipoprotein-lowering therapies, and important considerations for managing special populations of patients with dyslipidemias.

    This activity is provided by touchIME.

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in French, German, Spanish.
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchEXPERT OPINIONS

    The path from detection to personalized long-term care for Fabry disease

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchIN CONVERSATION

    Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Brian Bergmark, ACC 2022: TRANSLATE-TIMI 70: Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol

    GO TO HUB

    CONFERENCE HUB

    Wolfgang Linke, ESC 2021 – Key Pathomechanisms of TTNtv-dilated Cardiomyopathy

    GO TO HUB

    JOURNALS

    Effect of left ventricular hypertrophy on long-term survival of patients with coronary artery disease following percutaneous coronary intervention

    GO TO ARTICLE

    JOURNALS

    Organic nitrates and tolerance in cardiovascular diseases: effects of isosorbide-2-mononitrate compared to traditional nitrates

    GO TO ARTICLE

    Topics covered in this activity

    Cardiovascular Disease / Atherosclerosis
    Register to touchCARDIO for FREE
    • Peer-reviewed journals and expert opinions
    • Interactive CME and e-learning modules
    • Video conference highlights
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from Novartis.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 17 October 2022.

    Claim Credit
    touchIN CONVERSATION
    Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice

    You may also be interested in...

    touchEXPERT OPINIONS

    The path from detection to personalized long-term care for Fabry disease

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchIN CONVERSATION

    Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Martha Gulati: The mission of the ASPC and promoting cardiovascular health

    GO TO HUB

    CONFERENCE HUB

    Roxana Mehran, ESC 2021 – the PARADISE-MI Trial

    GO TO HUB

    JOURNALS

    The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?

    GO TO ARTICLE

    JOURNALS

    The inhibitory effects of polysaccharide peptides (PsP) of Ganoderma lucidum against atherosclerosis in rats with dyslipidemia

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from Novartis.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 17 October 2022.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup